Published in Biotech Business Week, September 8th, 2003
On February 11, 2003, Lorus announced a formal clinical trial agreement between the NCI and Lorus in which the NCI will financially sponsor a series of phase II clinical trials to investigate the safety and efficacy of GTI-2040 in six different cancer indications, while Lorus will provide the drug.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.